Related Experiment Video
Updated: May 10, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Methylation markers for prostate cancer prognosis: a systematic review
Chun Chao1, Margaret Chi, Melissa Preciado
1Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA. chun.r.chao@kp.org
Cancer Causes & Control : CCC
|June 26, 2013
Summary
Evidence on DNA methylation markers for prostate cancer prognosis is inconclusive. Future research needs larger samples and diverse patient groups to clarify their predictive value.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer prognosis relies on accurate risk stratification.
- DNA methylation markers are emerging biomarkers with potential prognostic value.
Purpose of the Study:
- To systematically review evidence on DNA methylation markers for prostate cancer prognosis.
- To identify knowledge gaps for future research directions.
Main Methods:
- Systematic review of PubMed-searched studies on DNA methylation and prostate cancer outcomes.
- Qualitative summary of findings due to study heterogeneity.
- Methodological quality assessment of included studies.
Main Results:
- Paired-like homeodomain transcription factor 2 (PITX2) methylation showed association with biochemical recurrence in two studies.
- Sixteen studies analyzed tissue methylation, four analyzed circulating DNA methylation.
- Limitations include small sample sizes and inadequate adjustment for prognostic factors.
Conclusions:
- Current evidence on DNA methylation markers for prostate cancer prognosis is inconclusive.
- Future studies require large samples, adequate follow-up, and diverse patient populations.
- Investigating methylation in diagnostic biopsies may offer new insights.
